Ryniawec, J.M.; Coope, M.R.; Loertscher, E.; Bageerathan, V.; de Oliveira Pessoa, D.; Warfel, N.A.; Cress, A.E.; Padi, M.; Rogers, G.C.
GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics 2022, 12, 676.
https://doi.org/10.3390/diagnostics12030676
AMA Style
Ryniawec JM, Coope MR, Loertscher E, Bageerathan V, de Oliveira Pessoa D, Warfel NA, Cress AE, Padi M, Rogers GC.
GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics. 2022; 12(3):676.
https://doi.org/10.3390/diagnostics12030676
Chicago/Turabian Style
Ryniawec, John M., Matthew R. Coope, Emily Loertscher, Vignesh Bageerathan, Diogo de Oliveira Pessoa, Noel A. Warfel, Anne E. Cress, Megha Padi, and Gregory C. Rogers.
2022. "GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors" Diagnostics 12, no. 3: 676.
https://doi.org/10.3390/diagnostics12030676
APA Style
Ryniawec, J. M., Coope, M. R., Loertscher, E., Bageerathan, V., de Oliveira Pessoa, D., Warfel, N. A., Cress, A. E., Padi, M., & Rogers, G. C.
(2022). GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics, 12(3), 676.
https://doi.org/10.3390/diagnostics12030676